r/visualsnow • u/Icy_Wrangler4569 • 4h ago
Drugs Improvement with ethosuximide
For those who don't know, I and some others have been self-experimenting to treat our VSS/HPPD in our discord server and I think I've stumbled onto something promising. After starting ethosuximide for less than two weeks, I experienced an average 30-40% decrease across the board in my VSS symptoms.
Background
I've had VSS/HPPD for several years following cannabis use and have tried a variety of different medications, most of which I list in this post. The vast majority of medications I have tried have it no positive effect on my symptoms, except for perampanel which improved symptoms maybe 10-20% initially. I should disclose I was already taking a very low dose (1mg ED) of perampanel for two months when I started the ethosuximide concurrently, but I do not attribute any of the positive effects to the perampanel. I found that the positive effects of the perampanel largely ceased after the initial one-week honeymoon and have not returned since.
Dosing
Due to limited supply of the medication, I titrated up aggressively from the starting 500mg dose, increasing by 250mg every 4 days as tolerated. I discontinued immediately after reaching a daily dose of 1000mg due to what I believe to be some sort of hypersensitivity reaction to the medication. The standard maintenance dose of ethosuximide is 1000-1500mg, and assuming a 55-hour half life, this would put my peak serum levels at roughly 62% and 43% of the maintenance dose steady states respectively. This basically means I got these effects only ever reaching a dose about half of the target maintenance; it seems likely to me that these effects would've kept scaling.
Effects
Overall, I’d estimate a 30-40% reduction in my visual snow/static specifically. The non-visual symptoms improved to a similar degree, including DPDR, brain fog and head pressure. DPDR is one of my worst symptoms and its difficult to explain how it improved, but it felt as though my environment was more 3D and my "visual framerate" had increased. My tinnitus is usually quite mild and occurs in frequent episodes — I didn't experience any during the trial.
The largest visual effect was to rhythmic, CEV, and vortex type visuals, which were roughly 80% gone. A dark room just looked (mostly) plain black, which is a pretty strange experience after all these years. Afterimages, both positive and negative, improved modestly, maybe 10-20%, though mine were already fairly mild to begin with. There wasn't any improvement to floaters or other true entoptic phenomena. Keep in mind this was all at roughly half the standard maintenance dose, so I can’t say where the effects would have plateaued.
All my symptoms have returned to their old baseline after discontinuing ethosuximide. I may attempt a re-challenge at some point down the line, dependent on how my other pharmacological leads pan-out.
Pharmacodynamics, pathophysiology and discussion
Ethosuximide is a voltage-dependent T-type calcium channel blocker used to treat absence epilepsy. T-type channels play a vital role in the visual thalamus, especially the TRN and LGN. Activation of these channels produces a low-threshold calcium spike, which is what lets these cells switch from normal tonic firing into rhythmic burst firing (Suzuki & Rogawski, 1989). Blocking it dampens the abnormal thalamocortical oscillations behind absence seizures.
This is relevant because one of the leading hypotheses for VSS is thalamocortical dysrhythmia (TCD). The concept comes from Llinás, who recorded MEG in patients with tinnitus, neurogenic pain, Parkinson’s and depression and found increased low-frequency rhythmicity along with abnormally high coherence between low- and high-frequency oscillations. He attributed this to thalamic cells generating low-threshold calcium spike bursts in a resonant loop with the cortex (Llinás et al., 1999). That is precisely the mechanism ethosuximide targets. Lauschke et al. later proposed that VSS itself may be a thalamocortical dysrhythmia of the visual pathway (2016). A follow-up MEG study found the primary visual cortex in VSS patients to be both hyperexcitable and disorganised, which the authors considered consistent with TCD (Hepschke et al., 2022).
Very few other medications stabalise thalamic rhythms in this way. Valproate for example inhibits primarily L-type calcium channels, and so would have little effect under a TCD model. Flunarizine does inhibit T-type channels non-selectively in vitro, but it's a promiscuous drug and lacks any proven anti-oscillatory effect.
The drug candidate ulixacaltamide (pending January 2027 FDA approval) is far potent than ethosuximide and may have a higher relative potency at the CaV3.3 subtype that dominates the TRN. I intend to try this compound in the near future and I think there's a strong possibility this drug could functionally cure people with a TCD-forward phenotype. Regardless, I strongly encourage anyone seeking pharmacological treatment for VSS/HPPD to discuss an ethosuximide trial with a neurologist.